PA
ALGS icon

Procyon Advisors’s Aligos Therapeutics ALGS Stock Holding History

Procyon Advisors’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-800
Closed -$19.6K – 521
2024
Q1 		$19.6K Buy
+800
New +$15.9K ﹤0.01% 509

Other funds holding ALGS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Procyon Advisors's ALGS Position: Q2 2024 in Review

Procyon Advisors sold out of Aligos Therapeutics (ALGS) in Q2 2024, closing a stake of 800 shares — an estimated $19.6K sold.

Procyon Advisors first reported a position in ALGS in Q1 2024 and held it in 1 quarter. The position peaked at $19.6K in Q1 2024. 48 funds tracked by Wall St. Rank hold ALGS as of Q2 2024.

  • Procyon Advisors reported no remaining Aligos Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Procyon Advisors sold 800 Aligos Therapeutics shares in Q2 2024, an estimated $19.6K.
  • Procyon Advisors first reported a position in Aligos Therapeutics in Q1 2024 and held it in 1 quarter.
  • Procyon Advisors's Aligos Therapeutics position peaked at $19.6K in Q1 2024.
  • 48 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2024.

Based on Procyon Advisors's 13F filing for Q2 2024, filed 2 Aug 2024.